Table 1 Clinical information of patients in the high-, low-immune score groups, training set, and validating set
Characteristics | Total (N = 378) | High (N = 185) | Low (N = 193) | Training (N = 189) | Valiating (N = 189) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Age at diagnosis (y) | 59(30–87) | 58(34–87) | 61(30–87) | 60(30–85) | 58(36–87) | |||||
Overall Survival (m) | 34.13(0.27–182.7) | 35.3(0.3-155.5) | 31.63(0.27–182.7) | 32.97(0.27–155.5) | 35.1(0.53–182.7) | |||||
Stage | ||||||||||
 I | 1 | 0.26% | 1 | 0.54% | 0 | 0.00% | 1 | 0.53% | 0 | 0.00% |
 II | 23 | 6.08% | 14 | 7.57% | 9 | 4.66% | 11 | 5.82% | 12 | 6.35% |
 III | 294 | 77.78% | 139 | 75.14% | 155 | 80.31% | 142 | 75.13% | 152 | 80.42% |
 IV | 57 | 15.08% | 30 | 16.22% | 27 | 13.99% | 33 | 17.46% | 24 | 12.70% |
 - | 3 | 0.79% | 1 | 0.54% | 2 | 1.04% | 2 | 1.06% | 1 | 0.49% |
Immune score (mean) | 34.27 (-14.15-84.41) | 50.21 (34.33–84.41) | 19.00 (-14.15-34.13) | 33.08 (-8.93-80.46) | 35.46 (-14.15-84.41) | |||||